Stone Formers Found to Be at Higher Risk for MI
Individuals who form kidney stones are at increased risk for myocardial infarction (MI) independent of CKD and other risk factors, according to researchers.
Diagnosis & Disease Information
Surveillance a Suitable Option for Low-Risk PCa
Active surveillance may be a suitable option for many men with low-risk prostate cancer (PCa), Swedish researchers concluded.
Post-RP Statins May Lower PSA Relapse Risk
SAN FRANCISCO—Initiating statin therapy after radical prostatectomy (RP) may decrease the risk of biochemical recurrence of prostate cancer, new data suggest.
Report: Data Do Not Justify Advised BP Goals in CKD
The target BP level of less than 130/80 mm Hg for CKD patients—which is recommended by a Kidney Disease Outcomes Quality Initiative guideline—is not definitively supported by scientific data and could potentially lead to adverse effects.
PSA Testing Found to Reduce Prostate Cancer Mortality
Deaths from prostate cancer (PCa) fell by almost half after 14 years of biennial screening, according to data from a Swedish study.
Cardiovascular Events Halt Study of Testosterone Gel
A study of testosterone supplementation in older men was terminated after daily application of a testosterone gel was associated with a significantly increased risk of cardiovascular (CV) adverse events.
CKD, Low Income Linked in Blacks
Low socioeconomic status (SES) increases blacks’ risk of developing CKD nearly twofold, but does not increase the risk in whites, according to a recent report in the American Journal of Kidney Diseases (2010;55:977-980).
Heart Beat May Signal Kidney Risk
A high resting heart rate and low beat-to-beat heart rate variability raises the odds of developing kidney disease, according to a study that examined data from 13,241 participants in the Atherosclerosis Risk in Communities study.
Acupuncture May Ease Hot Flashes from ADT
Acupuncture may be an effective treatment for hot flashes in men receiving androgen deprivation therapy (ADT) for prostate cancer (PCa), according to findings published online in Urology.
New Biologic Agent May Benefit Men with CRPC
CHICAGO—Tasquinimod, a novel biologic agent, may significantly slow the rate of disease progression and improve progression-free survival in patients with metastatic castrate-resistant prostate cancer (CRCP), according to a new study presented at the American Society of Clinical Oncology annual meeting.
- Loading...
Loading...
Loading... 
Loading...